{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":2,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04384484\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"LOTIS 5","nct_id":"NCT04384484","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lotis-5-nct04384484. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"LOTIS 5","arms":[{"description":"Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.\n\nParticipants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m\\^2 Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m\\^2 Q3W for up to 6 additional cycles.","label":"Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)","type":"EXPERIMENTAL"},{"description":"Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m\\^2 every Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m\\^2 Q3W for up to 6 additional cycles.","label":"Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)","type":"EXPERIMENTAL"},{"description":"Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 or Day 2 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m\\^2 + gemcitabine 1000 mg/m\\^2 + oxaliplatin 100 mg/m\\^2 every 2 weeks (Q2W) for up to 8 cycles.","label":"Part 2: Standard Immunochemotherapy (R-GemOx)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":440,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Loncastuximab Tesirine","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2026-04-28","lead_sponsor":"ADC Therapeutics S.A.","official_title":"A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-03-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to 4 years"}],"references":[],"start_date":{"date":"2020-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT04384484"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lotis-5-nct04384484"}